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Chronic medical conditions and/or their treatments may interact with aging to alter or even accelerate
brain senescence. Adult onset cancer, for example, is a disease associated with advanced aging and
emerging evidence suggests a proﬁle of subtle but diffuse brain injury following cancer chemotherapy.
Breast cancer is currently the primary model for studying these “chemobrain” effects. Given the wide-
spread changes to brain structure and function as well as the common impairment of integrated
cognitive skills observed following breast cancer chemotherapy, it is likely that large-scale brain net-
works are involved. Default mode network (DMN) is a strong candidate considering its preferential
vulnerability to aging and sensitivity to toxicity and disease states. Additionally, chemotherapy is asso-
ciated with several physiological effects including increased inﬂammation and oxidative stress that are
believed to elevate toxicity in the DMN. Biomarkers of DMN connectivity could aid in the development of
treatments for chemotherapy-related cognitive decline.
 2014 Elsevier Inc. Open access under CC BY-NC-ND license.1. Brain aging, cancer, and chemotherapy
With age, the brain undergoes numerous degenerative changes
that tend to result in a decline of cognitive function. Cognitive
decline occurs on a continuum with dementia being at the path-
ologic extreme. Age is the most consistent predictor of pathologic
cognitive decline including mild cognitive impairment (MCI) and
dementia (Kravitz et al., 2012). However, age is also a primary risk
factor for several major, noncentral nervous system (CNS) medical
conditions. Many of these conditions and/or their treatments
could potentially trigger an altered or accelerated brain aging
process.
Cancer is a common, age-related disease with most diagnoses
originating outside the CNS. Approximately 1 in 2 adults will be
diagnosed with cancer during their lifetime with a median age at
diagnosis of 66 years (Howlader et al., 2013). Advances in cancer
treatments, such as chemotherapy, have resulted in signiﬁcantly
improved survival rates leading to a large and growing cohort of
chemotherapy-exposed older adults. Chemotherapy is often
associated with persistent cognitive decline affecting antry and Behavioral Sciences,
RD, MC5795, Stanford, CA
472 8937.
Y-NC-ND license.estimated 78% of patients with non-CNS cancer (Wefel and
Schagen, 2012). Neuroimaging studies provide insight regarding
the effects of chemotherapy on cognition by demonstrating
subtle but diffuse brain injury (de Ruiter and Schagen, 2013;
Kaiser et al., 2014; Koppelmans et al., 2013; McDonald and
Saykin, 2013; Pomykala et al., 2013a; Scherling and Smith,
2013; Simo et al., 2013).
Thus far, most neuroimaging studies have focused on breast
cancer, which has become an initial model for investigating
chemotherapy-related brain injury in adult onset, non-CNS cancer.
Possible mechanisms of brain injury following breast cancer
chemotherapy (BCC) include direct toxicity to neural progenitor
cells (Monje and Dietrich, 2012), elevation of cytokine release and
oxidative stress (Conroy et al., 2013b; Ganz et al., 2013; Kesler et al.,
2013a; Pomykala et al., 2013b; Vardy et al., 2007), DNA damage and
epigenetic alterations (Conroy et al., 2013b), deﬁcient estrogen-
related protection of healthy brain cells (Hogervorst, 2013)
following chemotherapy-induced menopause (Conroy et al.,
2013a), and altered cerebral blood supply through blood vessel
damage (Seigers et al., 2010) and/or chemotherapy-induced anemia
(O’Shaughnessy, 2003). Chemotherapy-related mechanisms
interact with other factors including cancer pathogenesis (Kesler
et al., 2011), allostatic load (Miller et al., 2008), and genetic varia-
tions (Ahles and Saykin, 2007). Therefore, BCC research has broad
implications for neuroscience in terms of the effects of various
physiological factors on brain-behavior relationships. This research
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neuroscience for non-CNS medical conditions and provides an op-
portunity for interdisciplinary approaches to intervention including
neuropsychological rehabilitation, physical activity, and nutrition,
among others.
Many of the candidate mechanisms for BCC-related brain injury
overlap signiﬁcantly with those involved in aging (Ahles 2012;
Koppelmans et al., 2013; Mandelblatt et al., 2013). Accordingly,
older patients tend to have poorer cognitive outcome following BCC
(Ahles et al., 2010). Gray matter atrophy following BCC is analogous
to approximately 4 years of aging on the brain (Koppelmans et al.,
2012). Roughly 30% of BCC patients demonstrate a new onset of a
previously nonexistent cognitive deﬁcit at long-term follow up,
suggesting possible progressive decline (Wefel et al., 2010). The
presence of the APOE ε4 allele is a common risk factor for both
dementia and BCC-related cognitive dysfunction (Ahles et al.,
2003).
Aging is associated with microglial activation, causing increased
release of proinﬂammatory cytokines (Lynch, 2010), and chronic
neuroinﬂammation is associated with dementia (Herrup, 2010).
BCC survivors show elevated neurochemical markers of microglial
activity (i.e., myo-inositol) (Kesler et al., 2013b) and increased pe-
ripheral proinﬂammatory cytokines levels (Ganz et al., 2013; Kesler
et al., 2013a; Pomykala et al., 2013b; Vardy et al., 2007). Compared
with healthy women, BCC survivors show increased proin-
ﬂammatory cytokine levels with increased age (Kesler et al., 2013a).
Therefore, BCC is an interesting model for examining the in-
teractions among disease, aging, and neurodegeneration.
If chemotherapy accelerates the brain aging process,
chemotherapy-treated patients could be at higher risk for de-
mentia. Accordingly, one study suggested that BCC survivors are
20% more likely to be diagnosed with dementia (Heck et al., 2008).
Subsequent reports have not supported this ﬁnding (Baxter et al.,
2009; Du et al., 2010; Raji et al., 2009) though methodological
issues make conclusions difﬁcult (Koppelmans et al., 2013) and
further research in this area is imperative. Dementia risk could be
diagnosis-speciﬁc given that treatment regimens have been linked
with dementia incidence in colon cancer (Gupta and Lamont,
2004) but not breast cancer (Raji et al., 2009). Neuroimaging
biomarkers may offer signiﬁcantly increased sensitivity and reli-
ability in predicting cognitive outcome following BCC.
2. Aging and the default mode network
One of the most promising neuroimaging biomarkers of age-
and disease-related cognitive decline is reduction of default mode
network (DMN) connectivity (Damoiseaux, 2012). The increasing
investigation of large-scale brain networks such as DMN signals a
shift beyond theories relying on discrete cortical localization of
cognitive function and dysfunction. It is now known that special-
ized brain regions do not operate in isolation but participate in
integrated networks. These networks are dynamically coordinated
with specialized regions contributing to different networks in an
adaptive, context-speciﬁc manner (Hutchison et al., 2013; Sporns,
2011). Brain networks are organized such that they are simulta-
neously highly segregated and integrated allowing for optimal
efﬁciency of information processing and learning (Bullmore and
Sporns, 2012).
Even at rest, several different large-scale brain networks
demonstrate spontaneous, synchronous neuronal activity. These
intrinsic or “resting state” networks show higher activity during
rest and tend to be anti-correlated with activity in task-positive
networks (Fox et al., 2005; Raichle, 2011). Intrinsic network re-
gions show attenuation or “task-induced deactivation” (TID) and
are believed to modulate allocation of neural resources to supportgoal-oriented processes (Sambataro et al., 2010). The DMN, one of
the most commonly observed resting state networks, includes
precuneus, posterior cingulate, medial frontal, middle temporal and
lateral parietal regions, as well as hippocampus (Damoiseaux et al.,
2006). DMN is believed to support processes such as implicit
learning, autobiographical memory, prospection, monitoring the
external environment, creativity, and self-reﬂection (Abraham,
2013; Agnati et al., 2013; Qin and Northoff, 2011; Raichle, 2011;
Takeuchi et al., 2012). Both DMN functional connectivity and TID
tend to decrease with age and are markedly decreased in in-
dividuals with MCI or Alzheimer’s disease (Damoiseaux et al., 2012;
Greicius et al., 2004; Sheline et al., 2010). Disruptions of DMN
precede amyloid beta toxicity, the hallmark molecular pathology
associatedwith neurodegeneration, identifying individuals who are
cognitively normal but at high risk for dementia (Sheline et al.,
2010).
Amyloid beta accumulation naturally increases with age and
DMN is preferentially vulnerable to this toxicity (Buckner et al.,
2005). DMN regions are hubs, areas that participate in a large
number of functional interactions (Cole et al., 2010b) and therefore
have signiﬁcantly high metabolic demands (Lord et al., 2013).
DMN’s high energy requirements may make it more susceptible to
the reduction of physiological resources that occurs with age
including reduced metabolic capacity, cerebral blood ﬂow, and
glucose metabolism (Yao et al., 2011; Kapogiannis and Mattson,
2011). Additionally, inﬂammation increases with age and is asso-
ciated with elevated amyloid beta accumulation (Herrup, 2010).
Lower cognitive reserve also appears to degrade the DMN faster by
increasing amyloid beta deposition (Bero et al., 2011).
Alternatively, it has been suggested that amyloid beta toxicity
may be a consequence of neurodegeneration rather than a cause
(Armstrong, 2011). Amyloid beta is produced from amyloid pre-
cursor protein, which shows neuroprotective functions following
brain injury (Blennow et al., 2012). Therefore, the mechanism un-
derlying DMN’s increased vulnerability to age is not entirely clear.
DMN susceptibility to amyloid beta accumulation could result from
a combination of factors including both metabolic changes and
neuroprotective mechanisms that become dysregulated in the ag-
ing brain, which has decreased ability to adequately return to ho-
meostasis (Herrup, 2010). Additionally, APOE status inﬂuences
amyloid beta clearance (Verghese et al., 2013) indicating genetic
moderation of DMN vulnerability to amyloid beta toxicity.
3. Measuring DMN
DMN is primarily measured using functional magnetic reso-
nance imaging (fMRI) (Cole et al., 2010a; Margulies et al., 2010;
Zhang and Raichle, 2010) but has also been assessed using posi-
tron emission tomography (PET) (Buckner et al., 2008), electroen-
cephalography (Chen et al., 2013), and near-infrared spectroscopy
(Sasai et al., 2012). Structural connectivity of DMN can be measured
using volumetric magnetic resonance imaging or diffusion tensor
imaging (Alexander-Bloch et al., 2013).
3.1. Functional connectivity
If neural activity in a set of anatomically distinct brain regions is
synchronous, these regions are believed to be coordinating into a
functional network. Resting state fMRI (rsfMRI) is typically used to
assess functional connectivity of DMN and simply requires the
participant to lie passively in the scanner. A minimum duration of
5 minutes is associated with stable correlation strengths (Van Dijk
et al., 2010). However, robust brain network metrics can be ach-
ieved using a scan time of as little as 2 minutes if necessary
(Whitlow et al., 2011). RsfMRI is ideally acquired before task-based
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of speciﬁc cognitive processes on the resting state networks (Waites
et al., 2005; Northoff et al., 2010). Uncertainty remains as to
whether rsfMRI should be acquired with eyes open or closed as the
2 conditions can yield different results (Liu et al., 2013). Instructions
given to participants during rsfMRI, including whether or not to
close the eyes, should be consistent as ﬁndings can vary based on
instruction content (Benjamin et al., 2010). There are several other
potential participant-related confounds such as body weight and
caffeine consumption (Duncan and Northoff, 2013). However,
rsfMRI functional connectivity measures show strong stability and
test-retest reliability (Van Dijk et al., 2010).
Preprocessing of rsfMRI data is similar to that of task-based fMRI
including motion correction, spatial normalization, and smoothing.
However, rsfMRI data must be ﬁltered to the <0.1 Hz range of
spontaneous activity (Raichle, 2011; Whitﬁeld-Gabrieli and Ford,
2012). Because intrinsic activity occurs in such a low frequency
range, rsfMRI signal has increased susceptibility to nonneuronal
noise (Hutchison et al., 2013). Several approaches have been
described for minimizing these artifacts including independent
component analysis (ICA) (Boubela et al., 2013), principal compo-
nent analysis (Behzadi et al., 2007), and model-based methods
(Chang and Glover, 2009).
The 2 most common statistical approaches for rsfMRI functional
connectivity are seed-based correlation (SBC) and ICA. SBC is a
model-driven, univariate analysis where the time course of a region
of interest or seed, is correlated with the whole brain in a voxel-
wise manner at the individual participant level. The resulting cor-
relation matrix is typically normalized and can then be evaluated at
the group level (Whitﬁeld-Gabrieli and Ford, 2012). SBC seed sizes
and locations are often ambiguous leading to variability in results
(Cole et al., 2010a). One group recently introduced a data-driven
seed selection method that uses regional homogeneity (Yan et al.,
2013). Another data driven method, seed-based iterative cross-
correlation uses the voxels from an SBC-generated group level
connectivity map as a new seed, repeating this process until the
results converge (Yang et al., 2013).
ICA is a data-driven, multivariate method that works by
decomposing the unknown, mixed fMRI signal sources into maxi-
mally independent temporal or spatial activation maps (compo-
nents) (Calhoun and Adali, 2012). Individual components can
represent various brain networks as well as nonneuronal noise.
Therefore, components associated with DMN must be selected
before moving on to group level analyses. One approach is to
observe the power spectrum for each component and identify those
with a peak frequency in the intrinsic activity range (e.g.,
0.008e0.09 Hz). An automatic template matching procedure cal-
culates the “goodness of ﬁt” of a component with a spatial template
of interest (Greicius et al., 2004). Group ICA involves concatenation
of individual participants’ components and then back-
reconstructing them to ensure that components are consistently
ordered and can then be sorted temporally or spatially (Calhoun
et al., 2009). Partner-matching selects components by clustering
them based on similarity measures of spatial patterns across mul-
tiple within or between participants’ data sets (Wang and Peterson,
2008). Another automatic component selection method combines
spatial map ﬁltering, statistical tests, and spectral analysis (Storti
et al., 2013).
Intrinsic functional connectivity can also be extracted from task-
based block design or event related data (Fair et al., 2007). These
methods include concatenation of interleaved rest epochs or
removal of task-induced variance via regression (leaving the un-
derlying spontaneous activity) (Fox et al., 2006). There are several
disadvantages to such emulation of rsfMRI including exclusion of
the lower intrinsic frequencies and possible contamination byprevious task conditions (Fair et al., 2007). However, emulation is
advantageous for research groups with large existing data sets that
did not include rsfMRI.
Graph theory analysis provides a mathematical representation
of brain network topology as a system of interconnected elements
deﬁned by nodes (regions) and edges (connections) (Hosseini
et al., 2012a; Sporns, 2011). Brain networks tend to demonstrate
an efﬁcient, “small-world” organization where local connectivity
(clustering) is high and long-range connections (path lengths) are
economical (Sporns, 2011). Both global and local network metrics
can be calculated including modularity, which provides an
assessment of sub-networks (Stevens et al., 2012), hub analysis to
identify regions that are central to the network’s organization, and
attack analyses, which measure the network’s resilience (Hosseini
et al., 2012a). Methodological considerations include parcellation
scheme (Shen et al., 2013), choice of benchmark networks
(Hosseini and Kesler, 2013b), and thresholding (van Wijk et al.,
2010).
Multivoxel pattern analysis (MVPA) uses machine learning, a
branch of artiﬁcial intelligence, to automatically ﬁnd multivariate
patterns of brain structure and/or function that accurately predict
categorical or continuous variables (Mahmoudi et al., 2012; Orru
et al., 2012). MVPA is a highly sensitive method because of its
ability to use subtle signals across voxels that tend to be unde-
tectable by univariate analyses (Kamitani and Tong, 2005). The
functional connectivity correlation matrix or other extracted rsfMRI
measures can be used as features (i.e., input variables) for MVPA
classiﬁcation (Craddock et al., 2009). Linear support vector machine
is currently the most commonMVPA approach because of its ability
to handle large, high-dimensional data sets (Orru et al., 2012). Like
all the above methods, region of interest or feature selection, can
signiﬁcantly inﬂuence MVPA results (Mahmoudi et al., 2012).
3.2. Task-induced deactivation
Intrinsic network activity is attenuated during active tasks in a
dose-dependent manner with increased TID occurring with
increased task difﬁculty (Newton et al., 2011). Thus, TID can be
measured by identifying regions where activation is greater during
passive or low-load conditions comparedwith active or higher-load
conditions. In fMRI analyses, statistical modeling is generally
accomplished by creating contrasts or subtractions of various task-
related conditions or events. The aim is to examine activation
patterns associated with the effect of interest after removing
irrelevant or nuisance activations. These nuisance activations tend
to be accounted for using a control condition such as the 0-back
epochs in an n-back paradigm, for example. TID can bemeasured by
subtracting active task conditions from these control conditions
(Buckner et al., 2008). Because DMN TID occurs across tasks
(Sambataro et al., 2010), any fMRI task paradigm could potentially
be used.
4. DMN and chemotherapy
BCC-related cognitive dysfunction may represent a brain
network disorder given the widespread brain alterations that are
noted even decades after the treatment has ended (Pomykala et al.,
2013a). The coordinated, dynamic brain network response that
supports cognitive function depends critically on stable structural
networks (Sporns, 2011). Accordingly, intrinsic functional connec-
tivity is dependent on the underlying structural connectivity
(Damoiseaux et al., 2012; Hosseini and Kesler, 2013a). BCC is asso-
ciated with widespread reductions in white matter pathway
integrity in regions including cingulum and superior frontal oc-
cipital fasciculus (Deprez et al., 2013), which connect DMN regions.
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integration. BCC survivors also demonstrate reduced gray matter
volumes of DMN regions including precuneus, cingulate, lateral
parietal cortex, medial frontal gyrus, and hippocampus (Pomykala
et al., 2013a). Alterations in gray matter structure reduce brain
network functional specialization.
Most neuroimaging studies of BCC to date have involved task-
based fMRI methods. Although these studies did not aim to
examine DMN, they may collectively suggest reduced task-related
response of DMN regions. To investigate this possibility, a quan-
titative, anatomic likelihood estimate meta-analysis was per-
formed using GingerALE software version 2.3.2 (http://www.
brainmap.org/ale/) (Laird et al., 2011). A threshold of p < 0.05,
false discovery rate (nonparametric p-value) corrected with a 40
mmminimum cluster volume was used. All studies that used task-
based fMRI to study BCC and neurobiologic status were included.
PubMed searches included the keywords “cancer and chemo-
therapy and brain” or “cancer and chemotherapy and brain and
MRI”. Studies were also identiﬁed using recent reviews (de Ruiter
and Schagen, 2013; Pomykala et al., 2013a; Scherling and Smith,
2013; Simo et al., 2013). Six studies were identiﬁed (36 total foci,
258 total participants) (Conroy et al., 2013b; de Ruiter et al., 2011;
Kesler et al., 2009, 2011; Lopez Zunini et al., 2012; McDonald et al.,
2012). Meta-analysis indicated that abnormality of regions
involved in DMN was the most consistent ﬁnding, particularly in
the precuneus and medial frontal gyrus (Fig. 1). It is important to
note that DMN activity is reduced during tasks, not extinguished.
Task-related functional activation is believed to reﬂect a combi-
nation of spontaneous intrinsic network activity and response to
cognitive load (Fox et al., 2006). The present meta-analysis sug-
gests disrupted modulation of the DMN during various executive
and memory tasks following BCC. However, these ﬁndings are an
indirect assessment of DMN function and precuneus and medial
frontal gyrus participate in other brain networks as well.Fig. 1. Meta-analysis results showing regions of signiﬁcant (p < 0.05 corrected) overlap acr
size indicates increased cluster volume. PCN: precuneus (MNI coordinates: 40, 68, 42; 1
16; 16, 4, 50), PCing: posterior cingulate (28, 66, 18), CUN: cuneus (8, 68, 36), MFG:
cingulate (10, 20, 36). Figure created using BrainNet Viewer (http://www.nitrc.org/projec
resonance imaging.Application of graph theory in neuroimaging provides novel
insight regarding the topology of large-scale brain networks.
Increased age tends to be associated with reduced global efﬁciency
of large-scale brain networks, which is believed to represent a high
risk for dysconnectivity syndromes such as MCI and dementia (Wu
et al., 2013). Altered organization of large-scale structural and
intrinsic functional brain networks has been demonstrated in pa-
tients with brain tumor (Bartolomei et al., 2006; Bosma et al., 2009;
Heimans and Reijneveld, 2012) and patients exposed to intrathecal
chemotherapy (Hosseini et al., 2012a) as well as following BCC.
Hosseini et al. (2012b) examined organization of the large-scale
gray matter network in 37 BCC survivors compared with 38
healthy female controls. Breast cancer survivors had completed
chemotherapy an average of 4.5 years before the study enrollment.
Using graph theoretical analysis of 90 anatomic regions of interest,
a structural correlational brain network was constructed for each
group. Brain network statistics were computed, including mean
clustering coefﬁcient, a measure of network segregation, charac-
teristic path length, a measure of network integration and
small-worldness, a measure of the network’s ability to balance
segregation and integration. A permutation distribution was
created based on 1000 benchmark networks to determine the
signiﬁcance between group differences in network measures.
Results indicated that the BCC group demonstrated signiﬁcantly
reduced mean clustering (p¼ 0.03) and marginally reduced small-
worldness (p ¼ 0.08). Further, the control group demonstrated
expected hub regions in DMN including precuneus and middle
temporal gyrus whereas the BCC group did not. These ﬁndings
suggest that chemotherapy may disrupt participation of DMN re-
gions in the structural brain network.
A follow up study of the same cohort, demonstrated that orga-
nization of the global resting state functional brain network is also
disrupted following chemotherapy (Bruno et al., 2012). Consistent
with the previous study, mean clustering was signiﬁcantly reducedoss fMRI studies of BCC-related brain activation abnormality. Increased region marker
6, 72, 48), INS: insula (32, 18, 12), MedF: medial frontal gyrus (6, 30, 44; 4, 56,
middle frontal gyrus (26, 8, 52), MTG: middle temporal gyrus (56, 22, 5), Cing:
ts/bnv/). Abbreviations: BCC, breast cancer chemotherapy; fMRI, functional magnetic
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0.06). Additionally, characteristic path length was decreased in the
BCC group (p ¼ 0.05) indicating inefﬁcient functional network
integration. Again, the BCC group showed an altered hub proﬁle
with hippocampus not participating effectively in the functional
brain network. There were no signiﬁcant correlations between
network measures and cognitive or demographic factors. Although
neither of these brain network studies examined DMN speciﬁcally,
they provide evidence that BCC negatively impacts large-scale brain
networks, particularly with respect to DMN connectivity. However,
without a non-chemotherapy comparison group, it is not possible
to conclude from these studies that alterations in DMN are speciﬁc
to chemotherapy.
Altered brain network organization not only results in cognitive
impairment, but also reduces the brain’s resilience (Achard et al.,
2006; He et al., 2008; Hosseini et al., 2012a; Rubinov et al., 2009)
consistent with the frail phenotype of aging and reduced cognitive
reserve, both signiﬁcant predictors of pathologic cognitive decline
(Mandelblatt et al., 2013; Steffener and Stern, 2012; Stern 2012;
Whalley et al., 2004). Thus, even if a patient does not demon-
strate symptoms of chemotherapy-related cognitive dysfunction at
the time of initial evaluation, she may have increased vulnerability
for cognitive decline because of later disease, injury, and aging.
Decreased brain resilience may help explain the new onset of
previously nonexistent cognitive impairment and progressive
worsening of existing symptoms that have been noted in some
chemotherapy-treated breast cancer survivors (Wefel et al., 2010).
Two PET studies from the same research group examined both
task-related and resting-state cerebral metabolism in BCC
(Pomykala et al., 2013b; Silverman et al., 2007). The latter study
involved 16 BCC survivors 5e10 years post-chemotherapy and 8
healthy female controls (Silverman et al., 2007), whereas the
earlier study involved 23 chemotherapy-treated and 10 non-
echemotherapy-treated breast cancer patients assessed after
completing chemotherapy and 1 year later (Pomykala et al.,
2013b). Differences in PET activation were measured using
whole-brain voxelwise as well as region of interest analyses.
There were no between group differences or longitudinal differ-
ences in resting metabolism in either study although regions of
interest included some DMN regions. However, the study did not
actually aim to measure DMN and did not use TID or functional
connectivity methods. Therefore, it is not likely that DMN would
have been detected. PET studies provided the original evidence of
DMN through meta-analysis of TID (Buckner et al., 2008). PET’s
limited spatial and temporal resolution prevents functional con-
nectivity analysis at the individual participant level (Greicius
et al., 2007) and may result in inconsistent DMN results
compared with fMRI (Di et al., 2012).
Very few direct investigations of DMN in BCC have been
conducted to date. A case study by LaViolette et al. (2009)
examined change in DMN functional connectivity of a patient
with breast cancer from pre-chemotherapy to 3 months post-
chemotherapy compared with 5 control participants. RsfMRI
was used to measure functional connectivity and arterial spin
labeling was used to measure cerebral blood ﬂow. DMN con-
nectivity was deﬁned via SBC of posterior cingulate. Functional
connectivity between posterior cingulate and medial temporal
cortex and hippocampus were signiﬁcantly reduced post-
chemotherapy (p < 0.005). Additionally, cerebral blood ﬂow
was decreased in the lateral parietal cortex and precuneus (p <
0.001). This study preliminarily demonstrates that BCC-related
DMN changes can be measured at the individual level, poten-
tially providing valuable patient-speciﬁc information.
In a longitudinal study, Conroy et al. (2013a) investigated the
effect of chemotherapy-induced amenorrhea on task-inducedactivation as well as TID during an n-back working memory task
in 9 post-menopausal BC patients undergoing chemotherapy, 9 pre-
or peri-menopausal BC patients undergoing chemotherapy and 6
healthy female controls. TID was used to deﬁne DMN. There were
no signiﬁcant differences in activation or deactivation among the
groups. However, the chemotherapy-induced amenorrhea group
showed a signiﬁcant increase in the summed magnitude of acti-
vation and deactivation from pre-chemotherapy to 1 month post-
chemotherapy (p ¼ 0.011). This study suggests that alteration in
DMN TIDmay play a role inworkingmemory dysfunction following
BCC and that menopausal status is an important factor to consider
when evaluating the effects of BCC on DMN. However, the study
was very limited by the small sample size and lack of separation
between the contribution of task-induced activation versus DMN
TID to the overall ﬁndings.
Dumas et al. (2013) conducted an SBC analysis using an fMRI n-
back task in 9 patients with breast cancer before chemotherapy,
1 month and 1 year after completion of chemotherapy. Task-related
activation was removed via regression. An intraparietal sulcus seed
was used to interrogate dorsal attention network connectivity and a
posterior cingulate seed was used to investigate DMN. Dorsal
attention network connectivity was decreased at 1 month with
partial recovery at 1 year (p < 0.001, uncorrected). DMN connec-
tivity was also decreased at 1 month, speciﬁcally in the precuneus,
and did not recover at 1 year (p ¼ 0.001, uncorrected). N-back
performance did not change over time but self-rated memory dif-
ﬁculties decreased across all 3 time points. The authors did not
correlate fMRI and cognitive-behavioral data so it is unknown if
changes in connectivity were related to changes in memory com-
plaints. This study was limited by the emulation method of resting
state connectivity, small sample size, lack of control group, and
uncorrected statistical threshold. However, it provides further
preliminary evidence that DMN may show increased vulnerability
to chemotherapy characterized by limited recovery compared with
other brain networks.
To examine the speciﬁcity of BCC on DMN, Kesler et al. (2013c)
conducted MVPA of DMN functional connectivity in 30 BCC and
27 non-chemotherapy treated breast cancer survivors (4.9 
3.4 years post-chemotherapy) as well as 24 healthy female controls.
RsfMRI temporal correlations were calculated between 19 func-
tional regions of interest. Data were corrected for age, education,
psychiatric symptoms, and gray matter volume. The MVPA classi-
ﬁers were tested for each group pair as well disease stage (breast
cancer group only) using leave-one-out cross-validation. Permu-
tation analysis was conducted to determine classiﬁer signiﬁcance at
an alpha level adjusted for multiple comparisons.
Patterns of DMN connectivity signiﬁcantly distinguished
chemotherapy from both non-chemotherapy survivors and
healthy females with 90%e91% accuracy (p < 0.0001, receiver
operating characteristic [ROC] effect sizes: 0.97e0.98). The non-
chemotherapy group could not be distinguished from the
healthy control group and disease-stage classiﬁers also were not
signiﬁcantly better than chance. Connectivity within DMN re-
gions as well as connectivity between DMN and prefrontal re-
gions contributed the most to the classiﬁers indicating that these
connections were the most important for distinguishing the
groups. The classiﬁers were signiﬁcantly correlated with memory
complaints (p < 0.002) indicating that the more similar a par-
ticipant’s DMN connectivity to that of the chemotherapy group,
the lower the memory function. This study was limited by its
cross-sectional design but provides evidence that DMN may be
preferentially vulnerable to chemotherapy.
There are multiple different brain networks and chemotherapy
could potentially affect several of these. In fact, the proﬁle of BCC-
related cognitive impairments strongly suggests deﬁcit of central
S.R. Kesler / Neurobiology of Aging 35 (2014) S11eS19S16executive network and several studies have demonstrated altered
prefrontal cortex structure and function following chemotherapy
(de Ruiter and Schagen, 2013). Hosseini and Kesler (2013c) exam-
ined prefrontal functional connectivity in 27 chemotherapy treated
and 29 non-chemotherapy treated breast cancer survivors and 30
healthy females. fMRI data were obtained during an executive
function task. Functional connectivity was calculated between 12
frontal and parietal executive network regions of interest. MVPA
was conducted as described previously.
The MVPA classiﬁers signiﬁcantly distinguished between the
chemotherapy group and both the non-chemotherapy and health
female group with 71%e72% accuracy (p < 0.01, ROC: 0.71e0.72).
The classiﬁer for non-chemotherapy and healthy females was not
signiﬁcant. Connections between prefrontal and parietal regions
contributed the most in discriminating the chemotherapy group
from healthy females, whereas connections within prefrontal re-
gions had the greatest weight for discriminating the 2 breast cancer
groups. ROC effect sizes were much lower than those obtained for
the DMN classiﬁer (Kesler et al., 2013c). Additionally, the prefrontal
classiﬁer was associated with disease stage (p < 0.05) whereas the
DMN classiﬁer was not. These ﬁndings provide further evidence
that DMNmay be preferentially vulnerable to chemotherapy versus
disease severity or alternate treatments (e.g., radiation) compared
with other networks. However, prospective and longitudinal
studies are needed to further evaluate these ﬁndings.
5. Conclusions and future directions
Thus far, studies of DMN in BCC have been very limited. Many
have involved cross-sectional designs, small sample sizes, and/or
lacked appropriate comparison groups. However, indirect as well
as direct neuroimaging evidence suggests that DMN represents a
promising potential biomarker of chemotherapy-related brain
injury. The inclusion of rsfMRI in prospective study designs will
allow investigation of longitudinal changes in DMN connectivity.
Thus far, most neuroimaging studies of BCC have involved middle-
aged women (Ahles, 2012). Future efforts should focus on longi-
tudinal evaluation of very long-term survivors and/or older
patients to examine how BCC may moderate the effect of age on
DMN status.
To address the issue of small sample sizes, a standard neuro-
imaging battery analogous to that proposed by the International
Cognition and Cancer Task Force for harmonizing studies of
cognitive status (Wefel et al., 2011) is needed. This would allow
multisite research groups to combine data and increase statistical
power. This review suggests that the inclusion of rsfMRI is indi-
cated. RsfMRI can be used to assess multiple brain systems using
1 brief acquisition (Fox and Greicius, 2010). Resting state networks
closely correspond to a variety of active networks (Smith et al.,
2009) and rsfMRI has been used to decode networks associated
with various cognitive states including memory, executive control,
and salience, among others (Shirer et al., 2011). The simplicity of
rsfMRI makes it easy to standardize across sites and more feasible
for a wider range of participants, including older adults. Addition-
ally, task-related changes in brainmetabolism tend to be quite small
compared with the brain’s large resting state energy consumption
(Raichle and Mintun, 2006). RsfMRI may therefore provide a more
robust source of disease-related signal change (Fox and Greicius,
2010; Raichle and Mintun, 2006).
As noted previously, amyloid beta deposition is a key element
in the pathology of age-related cognitive decline and neuro-
degeneration (Herrup, 2010), but it is unknown if this toxicity
plays a role in BCC-related brain injury. Chemotherapy may
theoretically increase amyloid beta accumulation through eleva-
tion of inﬂammation and oxidative stress (Cai et al., 2011), alteredglucose metabolism (Baudino et al., 2011), and/or other factors.
Future studies combining APOE status, PET-based amyloid beta
markers (i.e., Florbetapir), and rsfMRI are required to examine the
interactions between aging, amyloid accumulation, genetic risk,
intrinsic brain networks, and chemotherapy.
The increased application of multivariate neuroimaging ana-
lyses to the study of chemobrain would signiﬁcantly advance this
ﬁeld of research. Most studies thus far have used mass univariate
methods, which are very limited with respect to evaluation of
large-scale networks as well as prediction of individual patient
outcome. Chemotherapy treatment is the only situation where it
is known in advance that a potential brain injury is about to
occur. With further reﬁnement of MVPA algorithms, baseline
neuroimaging could be used to predict which patients are at
highest risk for persistent chemotherapy-related brain injury.
This information could potentially inform treatment regimen
decision-making and prioritize patients for early interventions.
The inclusion of multimodal DMN biomarkers, such as a combi-
nation of rsfMRI and diffusion tensor imaging, may also improve
prediction accuracy. MVPA methods could help separate the
neurobiological effects of different treatments (e.g., chemo-
therapy vs. endocrine therapy) as well as psychiatric symptoms
(e.g., depression, fatigue vs. chemotherapy).
Finally, further study of DMN’s role in chemotherapy-related
cognitive decline could aid in the development of interventions.
Both cognitive and physical exercise have been shown to increase
DMN functional connectivity in healthy adults (Takeuchi et al.,
2013; Voss et al., 2010). Medication that has shown promise in
improving chemobrain symptoms (i.e., modaﬁnil) improves DMN
TID in healthy adults (Minzenberg et al., 2011). Additionally,
given the strong link between DMN decline and metabolic pro-
cesses, DMN biomarkers associated with chemotherapy may
provide an important opportunity for assessing nutritional in-
terventions. For example, regulators of mitochondrial metabolic
activity (e.g., B-vitamins) and dietary energy restrictions may
reduce or prevent amyloid beta toxicity in the brain (Kapogiannis
and Mattson, 2011; Yao et al., 2011).
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